Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
69 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Inclusion Body Myositis (IBM) - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Inclusion Body Myositis (IBM) - Pipeline Review, H2 2016, provides an overview of the Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline landscape. Inclusion Body Myositis (IBM) is one of the inflammatory myopathies that involve inflammation of the muscles or associated tissues, such as the blood vessels that supply the muscles. IBM symptoms include progressive weakness of the muscles of the wrists and fingers, the muscles of the front of the thigh, and the muscles that lift the front of the foot. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Inclusion Body Myositis (IBM) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Inclusion Body Myositis (IBM) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Inclusion Body Myositis (IBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 2, 2 and 2 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively for Inclusion Body Myositis (IBM). Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Inclusion Body Myositis (IBM) (Musculoskeletal Disorders). - The pipeline guide reviews pipeline therapeutics for Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Inclusion Body Myositis (IBM) (Musculoskeletal Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Inclusion Body Myositis (IBM) Overview 7 Therapeutics Development 8 Pipeline Products for Inclusion Body Myositis (IBM) - Overview 8 Pipeline Products for Inclusion Body Myositis (IBM) - Comparative Analysis 9 Inclusion Body Myositis (IBM) - Therapeutics under Development by Companies 10 Inclusion Body Myositis (IBM) - Therapeutics under Investigation by Universities/Institutes 11 Inclusion Body Myositis (IBM) - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Inclusion Body Myositis (IBM) - Products under Development by Companies 15 Inclusion Body Myositis (IBM) - Products under Investigation by Universities/Institutes 16 Inclusion Body Myositis (IBM) - Companies Involved in Therapeutics Development 17 Acceleron Pharma, Inc. 17 Escala Therapeutics, Inc. 18 Milo Biotechnology LLC 19 Nobelpharma Co., Ltd. 20 Novartis AG 21 Orphazyme ApS 22 Ultragenyx Pharmaceutical Inc. 23 Inclusion Body Myositis (IBM) - Therapeutics Assessment 24 Assessment by Monotherapy Products 24 Assessment by Target 25 Assessment by Mechanism of Action 27 Assessment by Route of Administration 29 Assessment by Molecule Type 31 Drug Profiles 33 AAV1-Follistatin - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 ACE-083 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 aceneuramic acid - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 ALZ-801 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 arimoclomol - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 bimagrumab - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 DEXM-74 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 Gene Therapy for Hereditary Inclusion Body Myopathy - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 UX-001P - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 UX-007 - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 Inclusion Body Myositis (IBM) - Dormant Projects 58 Inclusion Body Myositis (IBM) - Product Development Milestones 59 Featured News & Press Releases 59 Jul 27, 2016: Ultragenyx Announces Completion of Enrollment in Phase 3 Study of Aceneuramic Acid Extended Release (Ace-ER) in GNE Myopathy 59 Apr 21, 2016: MorphoSys : MorphoSys Provides Update on Results From Partner Phase 2b/3 RESILIENT Study of Bimagrumab 59 Oct 02, 2015: Ultragenyx Announces Aceneuramic Acid Prolonged Release Marketing Authorization Application Filed and Accepted for Review by European Medicines Agency 60 May 28, 2015: Ultragenyx Announces First Patient Enrolled in Global Phase 3 Study of Aceneuramic Acid (Sialic Acid) Extended Release in GNE Myopathy 60 Jan 12, 2015: Ultragenyx Announces Intent to File for Conditional Approval in Europe for Sialic Acid Extended-Release Tablets in Hereditary Inclusion Body Myopathy 61 Oct 13, 2014: Ultragenyx Announces Interim Data From Phase 2 Extension Study of Sialic Acid Extended-Release at International Congress of the World Muscle Society 61 Apr 30, 2014: Ultragenyx Announces Positive Data From Phase 2 Study of Sialic Acid Extended-Release at Emerging Sciences Session of American Academy of Neurology Annual Meeting 62 Dec 20, 2013: Ultragenyx Announces Results from Phase 2 Study of Sialic Acid Extended-Release Treatment in Hereditary Inclusion Body Myopathy 63 Oct 02, 2013: MorphoSys Collaborator to Start Pivotal Study with Bimagrumab 64 Sep 26, 2013: Ultragenyx Announces Three Abstracts Accepted for Poster Presentation at 18th Annual World Muscle Society Congress 65 Aug 20, 2013: Novartis receives FDA breakthrough therapy designation for BYM338 (bimagrumab) for sporadic inclusion body myositis (sIBM) 65 Jul 03, 2013: Ultragenyx Announces a Positive Signal in Interim Data from Phase 2 Study of UX001 in Hereditary Inclusion Body Myopathy 66 Dec 15, 2011: New Zealand Pharma Obtains FDA Orphan Drug Designation For DEX-M74 To Treat Hereditary Inclusion Body Myopathy 66 Appendix 68 Methodology 68 Coverage 68 Secondary Research 68 Primary Research 68 Expert Panel Validation 68 Contact Us 68 Disclaimer 69
List of Tables
Number of Products under Development for Inclusion Body Myositis (IBM), H2 2016 8 Number of Products under Development for Inclusion Body Myositis (IBM) - Comparative Analysis, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Number of Products under Investigation by Universities/Institutes, H2 2016 11 Comparative Analysis by Late Stage Development, H2 2016 12 Comparative Analysis by Clinical Stage Development, H2 2016 13 Comparative Analysis by Early Stage Development, H2 2016 14 Products under Development by Companies, H2 2016 15 Products under Investigation by Universities/Institutes, H2 2016 16 Inclusion Body Myositis (IBM) - Pipeline by Acceleron Pharma, Inc., H2 2016 17 Inclusion Body Myositis (IBM) - Pipeline by Escala Therapeutics, Inc. , H2 2016 18 Inclusion Body Myositis (IBM) - Pipeline by Milo Biotechnology LLC, H2 2016 19 Inclusion Body Myositis (IBM) - Pipeline by Nobelpharma Co., Ltd., H2 2016 20 Inclusion Body Myositis (IBM) - Pipeline by Novartis AG, H2 2016 21 Inclusion Body Myositis (IBM) - Pipeline by Orphazyme ApS, H2 2016 22 Inclusion Body Myositis (IBM) - Pipeline by Ultragenyx Pharmaceutical Inc., H2 2016 23 Assessment by Monotherapy Products, H2 2016 24 Number of Products by Stage and Target, H2 2016 26 Number of Products by Stage and Mechanism of Action, H2 2016 28 Number of Products by Stage and Route of Administration, H2 2016 30 Number of Products by Stage and Molecule Type, H2 2016 32 Inclusion Body Myositis (IBM) - Dormant Projects, H2 2016 58
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
